M
Maura Lodovici
Researcher at University of Florence
Publications - 92
Citations - 4123
Maura Lodovici is an academic researcher from University of Florence. The author has contributed to research in topics: Oxidative stress & DNA damage. The author has an hindex of 34, co-authored 89 publications receiving 3656 citations.
Papers
More filters
Journal ArticleDOI
Oxidative Stress and Air Pollution Exposure
TL;DR: As vehicular traffic is known to importantly contribute to PM exposure, its intensity and quality must be strongly relevant determinants of the qualitative characteristics of PM spread in the atmosphere.
Journal ArticleDOI
Polyphenol metabolites from colonic microbiota exert anti-inflammatory activity on different inflammation models.
Mar Larrosa,Cristina Luceri,E. Vivoli,Chiara Pagliuca,Maura Lodovici,Gloriano Moneti,Piero Dolara +6 more
TL;DR: Results indicate that HCAF, dOHPA, and HFER have anti-inflammatory activity in vitro and in vivo.
Journal ArticleDOI
Polycyclic aromatic hydrocarbon contamination in the Italian diet
TL;DR: Food is the major source of human exposure to PAHs, due in particular to the high consumption of contaminated cereal products, and the dietary intake ofPAHs was high compared with the calculated respiratory intake owing to polluted city air in Italy.
Journal ArticleDOI
Effect of natural phenolic acids on DNA oxidation in vitro.
TL;DR: Some natural phenolic acids, commonly present in food, have interesting protective activity against DNA oxidation in vitro and deserve further consideration as effective antioxidants in vivo.
Journal ArticleDOI
Novel Therapeutic Strategy to Prevent Chemotherapy-Induced Persistent Sensory Neuropathy By TRPA1 Blockade
Gabriela Trevisan,Serena Materazzi,Camilla Fusi,Alessandra Altomare,Giancarlo Aldini,Maura Lodovici,Riccardo Patacchini,Pierangelo Geppetti,Romina Nassini +8 more
TL;DR: A key role for early activation/sensitization of TRPA1 by oxidative stress by-products in producing CIPN is highlighted and prevention strategies for CIPn in patients are suggested through the use of early, short-term treatments with TRPA 1 antagonists.